drugset / Trial / NCT01766466

Cangrelor Ticagrelor Transition Study

NCT01766466

Phase 2 Completed 12 enrolled The Medicines Company
RandomizedFactorialOpen-label

Summary

To demonstrate that patients treated with cangrelor can be directly switched to oral ticagrelor and that patients treated with ticagrelor can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.

Timeline

Start
2013-01
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 4 ug/kg Intravenous
Subject Ticagrelor Small molecule 90 mg Oral
Subject Ticagrelor Small molecule 180 mg Oral